Year: 2021

JSP191 is well tolerated with no treatment-related adverse events in dose-escalation study Single-agent conditioning with JSP191 is associated with engraftment, immune reconstitution, and clinical benefitREDWOOD CITY, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data on JSP191 showing long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting. The accepted abstract is published and available on the ASH website here. Title: JSP191 As a Single-Agent Conditioning Regimen Results in Successful Engraftment,...

VANCOUVER, British Columbia, Dec. 08, 2021 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd.’s (TSX-V:SYH) (OTCQB:SYHBF) (Frankfurt:SC1P) (the “Company”) partner company Azincourt Energy (“Azincourt”) is pleased to announce that preparation of the winter road to allow access for the winter 2022 exploration program has commenced at the East Preston uranium project, located in the western Athabasca Basin, Saskatchewan, Canada. Project Location – Western Athabasca Basin, Saskatchewan, Canada:https://skyharbourltd.com/_resources/maps/SYH-Patterson-Lake.pdf Accurate Industries has been contracted to prepare and maintain the 60 km winter access road under the supervision of TerraLogic Exploration Inc. The road allows access from Provincial Highway 955 along the Cree Lake Road to the planned camp site on the East Preston Project. Several waterways...

Wilmington, DE and Or Yehuda, Israel, Dec. 08, 2021 (GLOBE NEWSWIRE) — Integrity Applications, Inc. (www.integrity-app.com) (OTCQB: IGAP), innovator of GlucoTrack®, a non-invasive device for measuring glucose levels in people with Type 2 diabetes and prediabetes, announced today that its shares of common stock were approved for listing on the Nasdaq Capital Market. Trading on Nasdaq is expected to commence on Friday, December 10, 2021 under its existing trading symbol, IGAP. The Company intends to file an application with Nasdaq to effect the previously announced name change to GlucoTrack, Inc. and related change in ticker symbol post the uplisting. “We are thrilled to announce the listing of our shares on Nasdaq, representing a significant milestone for the Company and its shareholders,” said Paul V. Goode, President...

WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the initiation of the CONTERNO study, a global, randomized Phase 3 trial of cosibelimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC). The primary endpoint for the CONTERNO Phase 3 trial is overall survival (OS), and the study is designed to support full regulatory approvals worldwide. James F. Oliviero, President and Chief Executive Officer of Checkpoint, stated, “We are excited to develop this combination in NSCLC, with the goal of extending the lives of patients with lung cancer and providing expanded access and fewer obstacles to potentially...

Unrivaled invites the Los Angeles Community to Join the Grand Opening Festivities SANTA ANA, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) — Unrivaled Brands, Inc. (OTCQX: UNRV) (“Unrivaled” or the “Company”) announced today the grand opening of the Company’s downtown Los Angeles People’s dispensary (“People’s DTLA”) is set for December 18th, 2021. The downtown location is the Company’s second People’s-affiliated and fifth overall dispensary in California. Joining People’s OC, a leading dispensary in the Orange County, People’s DTLA is in a preeminent location that provides an unrivaled experience, offering a wide selection of the Company’s leading cannabis brands in an immersive and modern retail experience. Situated in the core of the Los Angeles region, and one of the few dispensaries in downtown Los Angeles...

Achieves Record 9/30 Backlog of $13 Million LOWELL, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) — CSP Inc. (NASDAQ: CSPI), an award-winning provider of security and packet capture products, managed IT and professional services and technology solutions, reported financial and operating results for the fiscal 2021 fourth quarter and full year ended September 30, 2021, and provided a business update. Fourth Quarter/Full Year Operating Highlights and Recent AchievementsServices revenue grew 27% compared to the year-ago fourth quarter Favorable revenue mix led to a quarterly and annual gross margin of 41.7% and 32.8%, respectively Company-wide year-end backlog reached $13 million demonstrating solid customer demand for products and services and reflects a 165% increase over the prior year Prudent expense management and emergence and continued...

FORT MYERS, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) — Alico, Inc. (“Alico” or the “Company”) (Nasdaq: ALCO) announced today the release and publication of its inaugural annual Sustainability Report. This report emphasizes Alico’s commitment to measure and improve Alico’s Environmental, Social and Governance (“ESG”) strategy and performance. Key highlights:Alico is using Sustainability Accounting Standards Board (SASB) reporting standards to guide reporting of key Sustainability targets Critical topics include energy and climate, water, sustainable agriculture, food safety, supply chain sustainability, data privacy and security, health and safety, diversity and fair labor An ESG governance framework has been established, with oversight by the Company’s Board of Directors, to drive culture, accountability and continuous improvement Initial...

Visit the Company in Booth #1129 in the Exhibit Hall Elmsford, NY, Dec. 08, 2021 (GLOBE NEWSWIRE) — NanoVibronix, Inc., (NASDAQ: NAOV), a healthcare device company that produces the UroShield® and  PainShield® Surface Acoustic Wave (SAW) Portable Ultrasonic Therapeutic Devices, today announced it will showcase its PainShield products at the Workers’ Compensation Institute’s (WCI) 75th Annual Workers’ Compensation Educational Conference on December 12-15, 2021 at the Orlando World Center Marriott in Orlando, Florida.   Brian Murphy, CEO of Nanovibronix, stated, “The workers’ compensation market represents an enormous opportunity for our pain management devices. We are a new entrant to this market with the recent signing of an agreement with a national provider of solutions to facilitate reimbursement of our products. We look forward...

Leading British Grocer Moves Logistics Operations to Cloud-Based Platform with Help From Manhattan Associates WINNERSH, United Kingdom, Dec. 08, 2021 (GLOBE NEWSWIRE) — Manhattan Associates Inc. (NASDAQ: MANH) today announced that leading British grocer, Asda, has chosen Manhattan Active Warehouse Management to help evolve its logistics network in the UK, as the ‘Big Four’ grocer looks to implement future-ready, cloud-based systems agile enough to respond to changing customer and market conditions. Manhattan Active Warehouse Management will help Asda to more efficiently distribute stock, fulfil online orders and manage resources, enabling it to adapt to fluctuations and ultimately, provide better choice and service to its 18 million+ weekly customers. In addition to delivering a step change in accelerating the speed of innovation,...

FLORHAM PARK, N.J., Dec. 08, 2021 (GLOBE NEWSWIRE) — Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced a poster presentation featuring data from the company’s ongoing Phase 2 CLOVER-1 study of iopofosine I-131 at the American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually December 11-14, 2021. The poster will highlight data from eleven multiple myeloma patients who were at least triple class refractory (immunomodulatory agent, proteasome inhibitor and monoclonal antibody) that were treated with iopofosine I-131 in the company’s Phase 2 CLOVER-1 study, with data current as of the end of May 2021. Details for the poster presentation are...